NasdaqGS:REGN

Stock Analysis Report

Executive Summary

Regeneron Pharmaceuticals, Inc., a biopharmaceutical company, discovers, invents, develops, manufactures, and commercializes medicines for treating various medical conditions worldwide.

Snowflake

Fundamentals

Flawless balance sheet and slightly overvalued.


Similar Companies

Share Price & News

How has Regeneron Pharmaceuticals's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: REGN has not had significant price volatility in the past 3 months.


Market Performance


7 Day Return

3.7%

REGN

0.7%

US Biotechs

0.2%

US Market


1 Year Return

-1.0%

REGN

5.6%

US Biotechs

12.2%

US Market

Return vs Industry: REGN underperformed the US Biotechs industry which returned 5.6% over the past year.

Return vs Market: REGN underperformed the US Market which returned 12.2% over the past year.


Shareholder returns

REGNIndustryMarket
7 Day3.7%0.7%0.2%
30 Day11.4%8.3%3.5%
90 Day14.0%4.7%6.3%
1 Year-1.0%-1.0%6.5%5.6%14.7%12.2%
3 Year-16.4%-16.4%13.9%10.3%47.8%38.3%
5 Year-16.7%-16.7%4.7%-0.2%62.1%44.1%

Price Volatility Vs. Market

How volatile is Regeneron Pharmaceuticals's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Regeneron Pharmaceuticals undervalued compared to its fair value and its price relative to the market?

17.7%

Undervalued compared to fair value


Share Price vs. Fair Value

Below Fair Value: REGN ($338.39) is trading below our estimate of fair value ($411.14)

Significantly Below Fair Value: REGN is trading below fair value, but not by a significant amount.


Price To Earnings Ratio

PE vs Industry: REGN is poor value based on its PE Ratio (17.2x) compared to the Biotechs industry average (16.9x).

PE vs Market: REGN is good value based on its PE Ratio (17.2x) compared to the US market (18.1x).


Price to Earnings Growth Ratio

PEG Ratio: REGN is poor value based on its PEG Ratio (2.7x)


Price to Book Ratio

PB vs Industry: REGN is overvalued based on its PB Ratio (3.5x) compared to the US Biotechs industry average (2.8x).


Next Steps

Future Growth

How is Regeneron Pharmaceuticals forecast to perform in the next 1 to 3 years based on estimates from 23 analysts?

6.5%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: REGN's forecast earnings growth (6.5% per year) is above the savings rate (2.7%).

Earnings vs Market: REGN's earnings (6.5% per year) are forecast to grow slower than the US market (14.3% per year).

High Growth Earnings: REGN's earnings are forecast to grow, but not significantly.

Revenue vs Market: REGN's revenue (6% per year) is forecast to grow slower than the US market (7.3% per year).

High Growth Revenue: REGN's revenue (6% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: REGN's Return on Equity is forecast to be low in 3 years time (19.8%).


Next Steps

Past Performance

How has Regeneron Pharmaceuticals performed over the past 5 years?

36.6%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: REGN has a high level of non-cash earnings.

Growing Profit Margin: REGN's current net profit margins (28.1%) are lower than last year (28.2%).


Past Earnings Growth Analysis

Earnings Trend: REGN's earnings have grown significantly by 36.6% per year over the past 5 years.

Accelerating Growth: REGN's earnings growth over the past year (19.3%) is below its 5-year average (36.6% per year).

Earnings vs Industry: REGN earnings growth over the past year (19.3%) underperformed the Biotechs industry 86.5%.


Return on Equity

High ROE: REGN's Return on Equity (20.4%) is considered high.


Return on Assets


Return on Capital Employed


Next Steps

Financial Health

How is Regeneron Pharmaceuticals's financial position?


Financial Position Analysis

Short Term Liabilities: REGN's short term assets ($7.1B) exceeds its short term liabilities ($1.8B)

Long Term Liabilities: REGN's short term assets (7.1B) exceeds its long term liabilities (1.7B)


Debt to Equity History and Analysis

Debt Level: REGN is debt free.

Reducing Debt: REGN has no debt compared to 5 years ago when its debt to equity ratio was 11.2%.

Debt Coverage: REGN has no debt, therefore it does not need to be covered by operating cash flow.

Interest Coverage: REGN has no debt, therefore coverage of interest payments is not a concern.


Balance Sheet

Inventory Level: REGN has a high level of physical assets or inventory.

Debt Coverage by Assets: Insufficient data to determine if REGN's debt is covered by short term assets.


Next Steps

Dividend

What is Regeneron Pharmaceuticals's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

companyn/amarketbottom25%1.4%markettop25%3.6%industryaverage2.1%forecastin3Years0%

Current dividend yield vs market & industry

Notable Dividend: Unable to evaluate REGN's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate REGN's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if REGN's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if REGN's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of REGN's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

What is the CEO of Regeneron Pharmaceuticals's salary, the management and board of directors tenure and is there insider trading?

3.3yrs

Average management tenure


CEO

Leonard Schleifer (66yo)

31.8yrs

Tenure

US$26,520,555

Compensation

Dr. Leonard S. Schleifer, M.D., Ph.D., founded Regeneron Pharmaceuticals, Inc. in 1988 and has been its President and Chief Executive Officer since 1988. Dr. Schleifer served as the Chairman of Regeneron P ...


CEO Compensation Analysis

Compensation vs Market: Leonard's total compensation ($USD26.52M) is above average for companies of similar size in the US market ($USD11.01M).

Compensation vs Earnings: Leonard's compensation has been consistent with company performance over the past year.


Management Age and Tenure

3.3yrs

Average Tenure

59yo

Average Age

Experienced Management: REGN's management team is considered experienced (3.3 years average tenure).


Board Age and Tenure

21.8yrs

Average Tenure

68.5yo

Average Age

Experienced Board: REGN's board of directors are seasoned and experienced ( 21.8 years average tenure).


Insider Trading

Insider Buying: REGN insiders have only sold shares in the past 3 months.


Recent Insider Transactions

SellUS$2,492,88812 Nov 19
Neil Stahl
EntityIndividual
Shares7,364
Max PriceUS$341.38
SellUS$340,44008 Nov 19
Joseph Goldstein
EntityIndividual
Role
Member of the Board of Directors
Independent Director
Shares1,000
Max PriceUS$340.44
SellUS$48,611,80412 Sep 19
Sanofi
EntityCompany
Shares172,904
Max PriceUS$281.15
SellUS$305,93016 May 19
Joseph Goldstein
EntityIndividual
Role
Member of the Board of Directors
Independent Director
Shares1,000
Max PriceUS$305.93
SellUS$54,041,31613 Mar 19
Sanofi
EntityCompany
Shares131,115
Max PriceUS$412.17
SellUS$2,29414 Dec 18
Pindaros Vagelos
EntityIndividual
Role
Chairman of the Board
Chairman of the Board
Shares6
Max PriceUS$382.32

Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Management Team

  • Leonard Schleifer (66yo)

    Co-Founder

    • Tenure: 31.8yrs
    • Compensation: US$26.52m
  • George Yancopoulos (59yo)

    Founding Scientist

    • Tenure: 18.8yrs
    • Compensation: US$25.38m
  • Joe LaRosa (60yo)

    Executive VP

    • Tenure: 8.2yrs
    • Compensation: US$3.38m
  • Marion McCourt (59yo)

    Senior VP & Head of Commercial

    • Tenure: 1.8yrs
    • Compensation: US$10.28m
  • Bob Landry (55yo)

    Executive VP of Finance & CFO

    • Tenure: 6.1yrs
    • Compensation: US$9.36m
  • Beth Levine (55yo)

    Senior VP

    • Tenure: 0.8yrs
  • Daniel Van Plew (46yo)

    Executive VP and GM of Industrial Operations & Product Supply

    • Tenure: 11.6yrs
    • Compensation: US$9.01m
  • Sally Paull

    Senior Vice President of Human Resources

    • Tenure: 3.6yrs
  • Hala Mirza

    Senior Vice President of Corporate Communications & Citizenship

    • Tenure: 0.8yrs
  • Justin Holko

    Vice President of Investor Relations

    • Tenure: 0.4yrs

Board Members

  • Chris Poon (67yo)

    Independent Director

    • Tenure: 9yrs
    • Compensation: US$1.23m
  • Pindaros Vagelos (89yo)

    Chairman of the Board

    • Tenure: 24.8yrs
    • Compensation: US$6.35m
  • Leonard Schleifer (66yo)

    Co-Founder

    • Tenure: 31.8yrs
    • Compensation: US$26.52m
  • George Yancopoulos (59yo)

    Founding Scientist

    • Tenure: 18.8yrs
    • Compensation: US$25.38m
  • Art Ryan (76yo)

    Independent Director

    • Tenure: 16.8yrs
    • Compensation: US$1.23m
  • Michael Brown (78yo)

    Independent Director

    • Tenure: 28.4yrs
    • Compensation: US$1.23m
  • Joseph Goldstein (79yo)

    Independent Director

    • Tenure: 28.4yrs
    • Compensation: US$1.22m
  • George Sing (70yo)

    Independent Director

    • Tenure: 31.8yrs
    • Compensation: US$1.23m
  • Marc Tessier-Lavigne (59yo)

    Independent Director

    • Tenure: 8yrs
    • Compensation: US$1.21m
  • Bonnie Bassler (57yo)

    Independent Director

    • Tenure: 3.2yrs
    • Compensation: US$1.22m

Company Information

Regeneron Pharmaceuticals, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Regeneron Pharmaceuticals, Inc.
  • Ticker: REGN
  • Exchange: NasdaqGS
  • Founded: 1988
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$38.077b
  • Shares outstanding: 109.32m
  • Website: https://www.regeneron.com

Number of Employees


Location

  • Regeneron Pharmaceuticals, Inc.
  • 777 Old Saw Mill River Road
  • Tarrytown
  • New York
  • 10591
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
REGNNasdaqGS (Nasdaq Global Select)YesCommon StockUSUSDApr 1991
RGODB (Deutsche Boerse AG)YesCommon StockDEEURApr 1991
REGNSWX (SIX Swiss Exchange)YesCommon StockCHCHFApr 1991
0R2MLSE (London Stock Exchange)YesCommon StockGBUSDApr 1991
REGN *BMV (Bolsa Mexicana de Valores)YesCommon StockMXMXNApr 1991
REGNWBAG (Wiener Boerse AG)YesCommon StockATEURApr 1991
REGN34BOVESPA (Bolsa de Valores de Sao Paulo)BDR EACH 1 REP 0.2 COM USD0.001BRBRLMay 2019

Biography

Regeneron Pharmaceuticals, Inc., a biopharmaceutical company, discovers, invents, develops, manufactures, and commercializes medicines for treating various medical conditions worldwide. The company’s produ ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/11/14 23:41
End of Day Share Price2019/11/14 00:00
Earnings2019/09/30
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.